# Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers

> **NCT03868423** · PHASE2 · WITHDRAWN · sponsor: **Sameek Roychowdhury**

## Conditions studied

- Advanced Malignant Neoplasm
- ALK Fusion Protein Expression
- ALK Gene Amplification
- ALK Gene Mutation
- Locally Advanced Malignant Solid Neoplasm
- Metastatic Malignant Neoplasm in the Brain
- Metastatic Malignant Neoplasm in the Central Nervous System
- Metastatic Malignant Solid Neoplasm
- ROS1 Fusion Positive
- ROS1 Gene Amplification
- ROS1 Gene Mutation

## Interventions

- **DRUG:** Brigatinib
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT03868423
- **Lead sponsor:** Sameek Roychowdhury
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-03-20
- **Primary completion:** 2020-11-20
- **Final completion:** 2021-12-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI decision
- **Last updated:** 2022-02-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03868423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03868423, "Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03868423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*